Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2018 Feb;16(2):89-110. doi: 10.1080/14787210.2018.1425139. Epub 2018 Jan 16.

Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

El Chakhtoura NG1,2,3, Saade E1,2,3,4, Iovleva A5, Yasmin M1,2,4, Wilson B1,2,3, Perez F1,2,3, Bonomo RA1,2,3,4,6,7,8.

Author information

1
a Medicine , Case Western Reserve University School of Medicine , Cleveland , OH , USA.
2
b Research Services, Department of Internal Medicine, Louis Stokes Cleveland Veterans Affairs Medical Center , Case Western Reserve University School of Medicine , Cleveland , OH , USA.
3
c Geriatrics Research, Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center , Case Western Reserve University School of Medicine , Cleveland , OH , USA.
4
d Department of Medicine , University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland , OH , USA.
5
e Division of Infectious Diseases , University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.
6
f Departments of Pharmacology , Case Western Reserve University School of Medicine , Cleveland , OH , USA.
7
g Biochemistry , Case Western Reserve University School of Medicine , Cleveland , OH , USA.
8
h Molecular Biology and Microbiology , Case Western Reserve University School of Medicine , Cleveland , OH , USA.

Abstract

Non-fermenting Gram-negative bacilli are at the center of the antimicrobial resistance epidemic. Acinetobacter baumannii and Pseudomonas aeruginosa are both designated with a threat level to human health of 'serious' by the Centers for Disease Control and Prevention. Two other major non-fermenting Gram-negative bacilli, Stenotrophomonas maltophilia and Burkholderia cepacia complex, while not as prevalent, have devastating effects on vulnerable populations, such as those with cystic fibrosis, as well as immunosuppressed or hospitalized patients. Areas covered: In this review, we summarize the clinical impact, presentations, and mechanisms of resistance of these four major groups of non-fermenting Gram-negative bacilli. We also describe available and promising novel therapeutic options and strategies, particularly combination antibiotic strategies, with a focus on multidrug resistant variants. Expert commentary: We finally advocate for a therapeutic approach that incorporates in vitro antibiotic susceptibility testing with molecular and genotypic characterization of mechanisms of resistance, as well as pharmacokinetics and pharmacodynamics (PK/PD) parameters. The goal is to begin to formulate a precision medicine approach to antimicrobial therapy: a clinical-decision making model that integrates bacterial phenotype, genotype and patient's PK/PD to arrive at rationally-optimized combination antibiotic chemotherapy regimens tailored to individual clinical scenarios.

KEYWORDS:

Gram-negative bacteria; antimicrobial resistance; combination therapy; glucose-non-fermenting; mechanisms of resistance; nosocomial infections; precision medicine

PMID:
29310479
PMCID:
PMC6093184
DOI:
10.1080/14787210.2018.1425139
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center